Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.

Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, Yang X, Kurtz MM, Trujillo M, Gonzalez Trotter D, Feng D, Xu S, Eiermann G, Holahan MA, Rubins D, Conarello S, Niu X, Souza SC, Miller C, Liu J, Lu K, Feng W, Li Y, Painter RE, Milligan JA, He H, Liu F, Ogawa A, Wisniewski D, Rohm RJ, Wang L, Bunzel M, Qian Y, Zhu W, Wang H, Bennet B, LaFranco Scheuch L, Fernandez GE, Li C, Klimas M, Zhou G, van Heek M, Biftu T, Weber A, Kelley DE, Thornberry N, Erion MD, Kemp DM, Sebhat IK.

Science. 2017 Aug 4;357(6350):507-511. doi: 10.1126/science.aah5582. Epub 2017 Jul 13.

PMID:
28705990
2.

Spontaneous epithelioid hemangiosarcoma in a rhesus monkey (Macaca mulatta).

Tsuchiya T, Gray TL, Gatto NT, Forest T, Machotka SV, Troth SP, Prahalada S.

Comp Med. 2014 Aug;64(4):309-13.

3.

Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.

Forest T, Holder D, Smith A, Cunningham C, Yao X, Dey M, Frederick C, Prahalada S.

Endocrinology. 2014 Mar;155(3):783-92. doi: 10.1210/en.2013-1781. Epub 2014 Jan 1.

PMID:
24424056
4.

Recombinant rat and mouse growth hormones: risk assessment of carcinogenic potential in 2-year bioassays in rats and mice.

Farris GM, Miller GK, Wollenberg GK, Molon-Noblot S, Chan C, Prahalada S.

Toxicol Sci. 2007 Jun;97(2):548-61. Epub 2007 Mar 19.

PMID:
17372281
5.

Morphological changes in the kidney of dogs chronically exposed to exogenous growth hormone.

Molon-Noblot S, Laroque P, Prahalada S, Stabinski LG, Peter CP, Duprat P, van Zwieten MJ.

Toxicol Pathol. 2000 Jul-Aug;28(4):510-7.

PMID:
10930036
6.

Weekly administration of alendronate: rationale and plan for clinical assessment.

Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J.

Clin Ther. 2000 Jan;22(1):15-28. Review.

PMID:
10688387
7.

Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.

Prahalada S, Block G, Handt L, DeBurlet G, Cahill M, Hoe CM, van Zwieten MJ.

Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7.

PMID:
10226793
8.

Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.

Prahalada S, Rhodes L, Grossman SJ, Heggan D, Keenan KP, Cukierski MA, Hoe CM, Berman C, van Zwieten MJ.

Prostate. 1998 May 15;35(3):157-64.

PMID:
9582084
9.

Effect of chronic growth hormone administration on skeletal muscle in dogs.

Molon-Noblot S, Laroque P, Prahalada S, Stabinski LG, Hoe CM, Peter CP, Duprat P, van Zwieten MJ.

Toxicol Pathol. 1998 Mar-Apr;26(2):207-12.

PMID:
9547857
10.

Morphological changes in the pituitary gland of dogs chronically exposed to exogenous growth hormone.

Laroque P, Molon-Noblot S, Prahalada S, Stabinski LG, Hoe CM, Peter CP, Duprat P, van Zwieten MJ.

Toxicol Pathol. 1998 Mar-Apr;26(2):201-6.

PMID:
9547856
11.

Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs.

Prahalada S, Stabinski LG, Chen HY, Morrissey RE, De Burlet G, Holder D, Patrick DH, Peter CP, van Zwieten MJ.

Toxicol Pathol. 1998 Mar-Apr;26(2):185-200.

PMID:
9547855
12.

Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

Shen YT, Woltmann RF, Appleby S, Prahalada S, Krause SM, Kivilghn SD, Johnson RG, Siegl PK, Lynch JJ.

Am J Physiol. 1998 Feb;274(2):H456-66. doi: 10.1152/ajpheart.1998.274.2.H456.

PMID:
9486248
13.

Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).

Prahalada S, Tarantal AF, Harris GS, Ellsworth KP, Clarke AP, Skiles GL, MacKenzie KI, Kruk LF, Ablin DS, Cukierski MA, Peter CP, vanZwieten MJ, Hendrickx AG.

Teratology. 1997 Feb;55(2):119-31.

PMID:
9143092
14.

Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors.

Laroque PA, Prahalada S, Molon-Noblot S, Cohen SM, Soper K, Duprat P, Peter CP, van Zwieten MJ.

Prostate. 1995 Sep;27(3):121-8.

PMID:
7567690
15.

Induction of minisatellite DNA rearrangements by genotoxic carcinogens in mouse liver tumors.

Ledwith BJ, Joslyn DJ, Troilo P, Leander KR, Clair JH, Soper KA, Manam S, Prahalada S, van Zwieten MJ, Nichols WW.

Carcinogenesis. 1995 May;16(5):1167-72.

PMID:
7767981
16.

Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors.

Manam S, Shinder GA, Joslyn DJ, Kraynak AR, Hammermeister CL, Leander KR, Ledwith BJ, Prahalada S, van Zwieten MJ, Nichols WW.

Carcinogenesis. 1995 May;16(5):1113-9.

PMID:
7767973
17.

Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.

Cohen SM, Werrmann JG, Rasmusson GH, Tanaka WK, Malatesta PF, Prahalada S, Jacobs JG, Harris G, Nett TM.

Prostate. 1995 Feb;26(2):55-71.

PMID:
7531846
18.

Effects of porcine growth hormone on pregnancy and fetal/neonatal development in the rat.

Spence S, Mattson B, Vetter C, Cukierski M, Prahalada S.

Biol Neonate. 1995;68(1):62-74.

PMID:
7578639
19.

Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor.

Prahalada SR, Keenan KP, Hertzog PR, Gordon LR, Peter CP, Soper KA, van Zwieten MJ, Bokelman DL.

Urology. 1994 May;43(5):680-5.

PMID:
7513109
20.

Leydig cell hyperplasia and adenomas in mice treated with finasteride, a 5 alpha-reductase inhibitor: a possible mechanism.

Prahalada S, Majka JA, Soper KA, Nett TM, Bagdon WJ, Peter CP, Burek JD, MacDonald JS, van Zwieten MJ.

Fundam Appl Toxicol. 1994 Feb;22(2):211-9.

PMID:
8005373
21.

Effects of chronic oral administration of a selective 5 alpha-reductase inhibitor, finasteride, on the dog prostate.

Laroque PA, Prahalada S, Gordon LR, Noblot SM, Bagdon WJ, Duprat P, Peter CP, Van Zwieten MJ.

Prostate. 1994;24(2):93-100.

PMID:
8309848
22.

Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5 alpha-reductase inhibitor.

Clark RL, Anderson CA, Prahalada S, Robertson RT, Lochry EA, Leonard YM, Stevens JL, Hoberman AM.

Toxicol Appl Pharmacol. 1993 Mar;119(1):34-40.

PMID:
8385814
23.

Embryotoxicity studies of norfloxacin in cynomolgus monkeys. II. Role of progesterone.

Cukierski MA, Hendrickx AG, Prahalada S, Tarantal AF, Hess DL, Lasley BL, Peter CP, Tarara R, Robertson RT.

Teratology. 1992 Nov;46(5):429-38.

PMID:
1462247
24.

Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice.

Manam S, Storer RD, Prahalada S, Leander KR, Kraynak AR, Ledwith BJ, van Zwieten MJ, Bradley MO, Nichols WW.

Cancer Res. 1992 Jun 15;52(12):3347-52.

25.

Polymerase chain reaction/sequencing analysis of ras mutations in paraffin-embedded tissues as compared with 3T3 transfection and polymerase chain reaction/sequencing of frozen tumor deoxyribonucleic acids.

Goodrow TL, Prahalada SR, Storer RD, Manam SV, Leander KR, Kraynak AR, van Zwieten MJ, Nichols WW, Bradley MO.

Lab Invest. 1992 Apr;66(4):504-11.

PMID:
1583889
26.

Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors.

Goodrow TL, Storer RD, Leander KR, Prahalada SR, van Zwieten MJ, Bradley MO.

Mol Carcinog. 1992;5(1):9-15.

PMID:
1543544
27.

Activation of the Ki-ras gene in spontaneous and chemically induced lung tumors in CD-1 mice.

Manam S, Storer RD, Prahalada S, Leander KR, Kraynak AR, Hammermeister CL, Joslyn DJ, Ledwith BJ, van Zwieten MJ, Bradley MO, et al.

Mol Carcinog. 1992;6(1):68-75.

PMID:
1503645
28.

Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.

Cohen SM, Taber KH, Malatesta PF, Shpungin J, Berman C, Carlin JR, Werrmann JG, Prahalada S, Bryan RN, Cordes EH.

Magn Reson Med. 1991 Sep;21(1):55-70.

PMID:
1719333
29.

Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.

Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH, Slater EE.

Prostate. 1991;18(3):215-27.

PMID:
1850515
30.

Effects of seminal vesicle and coagulating gland ablation on fertility in rats.

Cukierski MA, Sina JL, Prahalada S, Robertson RT.

Reprod Toxicol. 1991;5(4):347-52.

PMID:
1806140
31.

Decreased fertility in male rats administered the 5 alpha-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation.

Cukierski MA, Sina JL, Prahalada S, Wise LD, Antonello JM, MacDonald JS, Robertson RT.

Reprod Toxicol. 1991;5(4):353-62.

PMID:
1666858
32.

Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5 alpha-reductase inhibitor.

Wise LD, Minsker DH, Cukierski MA, Clark RL, Prahalada S, Antonello JM, MacDonald JS, Robertson RT.

Reprod Toxicol. 1991;5(4):337-46.

PMID:
1666857
33.

DNA fingerprinting of 7,12-dimethylbenz[a]anthracene-induced and spontaneous CD-1 mouse liver tumors.

Ledwith BJ, Storer RD, Prahalada S, Manam S, Leander KR, van Zwieten MJ, Nichols WW, Bradley MO.

Cancer Res. 1990 Sep 1;50(17):5245-9.

34.

External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor.

Clark RL, Antonello JM, Grossman SJ, Wise LD, Anderson C, Bagdon WJ, Prahalada S, MacDonald JS, Robertson RT.

Teratology. 1990 Jul;42(1):91-100.

PMID:
2168096
35.

Morphologic development of the adrenal cortex in squirrel monkeys (Saimiri sciureus).

Miller CJ, Prahalada S, Coe C, Benirschke K.

J Med Primatol. 1990;19(7):651-61.

PMID:
2254916
36.

Embryotoxicity studies of norfloxacin in cynomolgus monkeys: I. Teratology studies and norfloxacin plasma concentration in pregnant and nonpregnant monkeys.

Cukierski MA, Prahalada S, Zacchei AG, Peter CP, Rodgers JD, Hess DL, Cukierski MJ, Tarantal AF, Nyland T, Robertson RT, et al.

Teratology. 1989 Jan;39(1):39-52.

PMID:
2718139
37.

Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon.

Rowland JM, Slikker W Jr, Holder CL, Denton R, Prahalada S, Young JF, Hendrickx AG.

Reprod Toxicol. 1989;3(3):197-202.

PMID:
2520523
38.

Preclinical evaluation of lovastatin.

MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL.

Am J Cardiol. 1988 Nov 11;62(15):16J-27J. Review.

PMID:
3055920
39.

Diethylstilbestrol-induced cervical and vaginal adenosis using the neonatal mouse model.

Prahalada S, Castracane VD, Hendrickx AG, Goldzieher JW.

Biol Reprod. 1988 May;38(4):935-43.

PMID:
3401547
40.

Early indicators of male reproductive toxicity.

Overstreet JW, Samuels SJ, Day P, Hendrickx AG, Prahalada S, Mast T, Katz DF, Sakai C.

Risk Anal. 1988 Mar;8(1):21-6.

PMID:
3287505
41.

Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate.

Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, Prahalada S, Günzel P.

Teratology. 1987 Feb;35(1):129-36.

PMID:
3563931
42.
43.

Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys.

Rowland JM, Robertson RT, Cukierski M, Prahalada S, Tocco D, Hendrickx AG.

Fundam Appl Toxicol. 1987 Jan;8(1):51-8.

PMID:
3556822
44.

Long-term evaluation of the diethylstilbestrol (DES) syndrome in adult female rhesus monkeys (Macaca mulatta).

Hendrickx AG, Prahalada S, Binkerd PE.

Reprod Toxicol. 1987-1988;1(4):253-61.

PMID:
2980390
45.

Inapparent carriers of simian acquired immune deficiency syndrome type D retrovirus and disease transmission with saliva.

Lerche NW, Osborn KG, Marx PA, Prahalada S, Maul DH, Lowenstine LJ, Munn RJ, Bryant ML, Henrickson RV, Arthur LO, et al.

J Natl Cancer Inst. 1986 Aug;77(2):489-96.

PMID:
3461210
46.
47.

Embryotoxicity and maternal serum concentrations of medroxyprogesterone acetate (MPA) in baboons (Papio cynocephalus).

Prahalada S, Carroad E, Hendrickx AG.

Contraception. 1985 Nov;32(5):497-515.

PMID:
2935368
48.

Evaluation of bendectin embryotoxicity in nonhuman primates: II. Double-blind study in term cynomolgus monkeys.

Hendrickx AG, Cukierski M, Prahalada S, Janos G, Booher S, Nyland T.

Teratology. 1985 Oct;32(2):191-4.

PMID:
4049276
49.

Evaluation of bendectin embryotoxicity in nonhuman primates: I. Ventricular septal defects in prenatal macaques and baboon.

Hendrickx AG, Cukierski M, Prahalada S, Janos G, Rowland J.

Teratology. 1985 Oct;32(2):179-89.

PMID:
4049275
50.

Calcinosis circumscripta in two rhesus monkeys.

Line SW, Ihrke PJ, Prahalada S.

Lab Anim Sci. 1984 Dec;34(6):616-8.

PMID:
6521431

Supplemental Content

Loading ...
Support Center